Press

Trading in subscription rights and BTAs in Acarix' rights issue will commence tomorrow

Trading in subscription rights and BTAs in Acarix' rights issue has been delayed, due to
late submission of the application to Nasdaq.
This situation is beyond Acarix control.
Trading will commence tomorrow, October 10. All other information in the press release
about Acarix rights issue, published earlier today is confirmed as accurate.

PR_Trading in subscription rights and BTAs in Acarix' rights issue will commence tomorrow

PM_Handeln med teckningsrätter och BTA i Acarix företrädesemission inleds imorgon.

About Acarix
Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor®System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor system calculates a patient-specific CAD-score non-invasively in less than10 minutes and can help rule out more than one third of patients with at least 96% certainty of not being sick (in a population with approx. 10% CAD prevalence). Acarix is listed on the Nasdaq First North Premier Growth Market (ticker: ACARIX). Redeye AB (+46 (0)8 121 576 90, certifiedadviser@redeye.se) is Certified Advisor of Acarix.

For more information, please visit www.acarix.com.